Search Result

Pathways Recommended:	Protein Tyrosine Kinase/RTK

Results for "

Receptor tyrosine kinase

" in MedChemExpress (MCE) Product Catalog:

By Targets:	Anaplastic lymphoma kinase (ALK) (2) Btk (4) DYRK (2) FLT3 (16) Syk (1) 5-HT Receptor (2) ADC Antibody (3) Adenosine Kinase (1) Akt (2) Antibiotic (1) Antibody-Drug Conjugates (ADCs) (1) Apoptosis (31) Autophagy (19) Bcl-2 Family (1) Bcr-Abl (2) BCRP (1) BMX Kinase (1) c-Fms (6) c-Kit (18) c-Met/HGFR (5) c-Myc (1) CaMK (1) Caspase (3) Discoidin Domain Receptor (5) E3 Ligase Ligand-Linker Conjugates (1) EGFR (23) Endogenous Metabolite (1) Ephrin Receptor (4) FGFR (19) GDNF Receptor (1) HIF/HIF Prolyl-Hydroxylase (1) IGF-1R (5) Insulin Receptor (7) Interleukin Related (2) IRAK (1) IRE1 (6) Isotope-Labeled Compounds (3) JAK (4) MAPKAPK2 (MK2) (1) Microtubule/Tubulin (1) Mitophagy (6) p38 MAPK (1) PDGFR (38) PERK (2) Phosphatase (2) Pim (1) PKA (1) PKC (1) PROTACs (1) Raf (7) RET (12) ROR (2) SHP2 (2) Src (14) STAT (2) TAM Receptor (11) TGF-β Receptor (1) Tie (7) Toll-like Receptor (TLR) (1) Topoisomerase (1) Trk Receptor (12) Tyrosinase (1) VEGFR (40) Wnt (1) β-catenin (1)
By Research Areas:	Cancer (135) Cardiovascular Disease (5) Endocrinology (4) Infection (1) Inflammation/Immunology (16) Metabolic Disease (7) Neurological Disease (9)
Click Chemistry:	Alkynes (3)

167

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

Natural
Products

151

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Targets Recommended: Btk Syk DYRK Pyk2 BRK FAK FLT3 Anaplastic lymphoma kinase (ALK)

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-112412

PDGFR Tyrosine Kinase Inhibitor III PDGF Receptor tyrosine kinase Inhibitor III	PDGFR	Neurological Disease
PDGFR Tyrosine Kinase Inhibitor III (PDGF Receptor Tyrosine Kinase Inhibitor III), a multikinase inhibitor, inhibits PDGFR, EGFR, FGFR, PKA, and PKC, respectively. PDGFR Tyrosine Kinase Inhibitor III can be used for the research of amyotrophic lateral sclerosis .

HY-18963

Lavendustin A RG-14355	EGFR	Cancer
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-18314

GW 441756 5+ Cited Publications	Trk Receptor Apoptosis	Neurological Disease Cancer
GW 441756 is a potent and specific nerve growth factor (NGF) receptor tyrosine kinases A (TrkA) inhibitor (IC₅₀=2 nM), which eliminates the BmK NSPK-induced neurite outgrowth .

HY-18316

RO495	JAK	Inflammation/Immunology
RO495 is a potent inhibitor of non-receptor tyrosine-protein kinase 2 (TYK2 kinase) .

HY-101756

SDZ281-977 SDZ-LAP 977	EGFR	Cancer
SDZ 281-977 is a derivative of the EGF receptor tyrosine kinase inhibitor Lavendustin A.

HY-101962

HNMPA	Insulin Receptor	Metabolic Disease
HNMPA is a membrane impermeable insulin receptor tyrosine kinase inhibitor. HNMPA inhibits serine and tyrosine autophosphorylation by the human insulin receptor. HNMPA has no effect on protein kinase C or cyclic AMP-dependent protein kinase activities

HY-114667

Lavendustin C6	EGFR	Others
Lavendustin C6 is a specific inhibitor of **tyrosine kinase*. Lavendustin C6 inhibits epidermal growth factor (EGF) receptor* tyrosine kinase with an EC₅₀ value of 0.05 μg/mL. Lavendustin C6 inhibits platelet-derived growth factor (PDGF)-induced inositol phosphate formation .

HY-164394

EMD 1204831	c-Met/HGFR	Cancer
EMD 1204831 is a potent and highly selective c-Met inhibitor which selectively suppresses the c-Met receptor tyrosine kinase activity with an IC₅₀ of 9 nM. EMD 1204831 can be utilized in cancer research .

HY-116116

Tafetinib SIM010603	c-Kit RET VEGFR	Cancer
Tafetinib (SIM010603) is an oral multi-targets receptor tyrosine kinases inhibitor. Tafetinib inhibitsstem cell factor receptor (Kit),*vascular endothelial growth factor receptor-2 (VEGFR-2),platelet-derived growth factor receptor-β (PDGFR-β),glial cell line-derived neurotrophic factor receptor* (Rearranged during Transfection; RET)*, andFms-like tyrosine* kinase-3 (FLT3)withIC₅₀values between 5.0 and 68.1 nmol/l. Tafetinib inhibits the phosphorylation ofPDGFR-βandVEGFR-2. Tafetinib inhibits endothelial cell proliferation, endothelial cells chemotaxis, and corneal angiogenesis .

HY-124146

BI1002494	Syk	Inflammation/Immunology
BI1002494 is an orally active, potent, and selective spleen tyrosine kinase (SYK) inhibitor. BI 1002494 exhibits an IC₅₀ of 115 nM in inhibiting high-affinity IgE receptor-mediated mast cell and basophil degranulation. BI1002494 can be utilized in immunology reesearch .

HY-159840

Fanregratinib	FGFR	Cancer
Fanregratinib is a fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor .

HY-18007

ALW-II-41-27 20+ Cited Publications Eph Receptor tyrosine kinase inhibitor	Ephrin Receptor	Cancer
ALW-II-41-27 is a Eph family tyrosine kinase inhibitor with an IC₅₀ of 11 nM for Eph2.

HY-18840

BBT594 3 Publications Verification NVP-BBT594	RET	Cancer
BBT594 is a potent receptor tyrosine kinase RET inhibitor, used for cancer treatment.

HY-159503

Segigratinib 3D185 free base; HH185 free base	Others	Cancer
Segigratinib is a fibroblast growth factor receptor tyrosine kinase inhibitor, with antineoplastic effect .

HY-152845

Ficonalkib	Anaplastic lymphoma kinase (ALK)	Cancer
Ficonalkib is a potent inhibitor of *Anaplastic lymphoma kinase* (ALK), the tyrosine kinase receptor**. Ficonalkib, can be used as an antineoplastic agent .

HY-101429

RG13022 Tyrphostin RG13022	EGFR	Cancer
RG13022 is a **tyrosine kinase** inhibitor; inhibits the autophosphorylation reaction of the EGF receptor with an IC₅₀ of 4 μM.

HY-12963

Dubermatinib 5+ Cited Publications TP-0903	TAM Receptor Apoptosis	Cancer
Dubermatinib (TP-0903) is a potent and selective Axl receptor tyrosine kinase inhibitor with an IC₅₀ value of 27 nM.

HY-13892

Dovitinib dilactic acid CHIR-258 dilactic acid; TKI258 dilactic acid	VEGFR	Cancer
Dovitinib (dilactic acid) is an orally active inhibitor of VEGF kinase. Dovitinib (dilactic acid) inhibits receptor tyrosine kinases (RTKs) involved in solid and hematologic cancers and tumor angiogenesis .

HY-100673

LM22A-4	Trk Receptor	Neurological Disease
LM22A-4 is a specific agonist of tyrosine kinase receptor B, used for neurological disease research.

HY-10331S

Regorafenib-d3 BAY 73-4506-d₃	VEGFR Autophagy PDGFR Raf RET	Cancer
Regorafenib-d₃ is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].

HY-148742

RET-IN-21	RET	Cancer
RET-IN-21 is an inhibitor of receptor tyrosine kinase (RET), with the IC ⁵⁰ of 4.4 μM, that has antitumor activity .

HY-145626

Ozuriftamab BA302	ADC Antibody	Cancer
Ozuriftamab is a naked human IgG1 kappa antibody of receptor tyrosine kinase-like orphan receptor 2 ROR2, can be used to synthesis ADC .

HY-112096

eCF506 2 Publications Verification	Src	Cancer
eCF506 is a highly potent and orally bioavailable inhibitor of the non-receptor tyrosine kinase Src with an IC₅₀ of less than 0.5 nM.

HY-P0177

123C4	Ephrin Receptor	Metabolic Disease
123C4 is a potent, selective and competitive agonist of the receptor tyrosine kinase EPHA4, with a K_i value of 0.65 μM .

HY-10407

SU 5402 5+ Cited Publications	VEGFR FGFR PDGFR	Cancer
SU 5402 is a potent multi-targeted receptor tyrosine kinase inhibitor with IC₅₀ of 20 nM, 30 nM, and 510 nM for VEGFR2, FGFR1, and PDGFRβ, respectively.

HY-P99969

Inetetamab	EGFR	Cancer
Inetetamab is a monoclonal antibody binding to domain IV of HER2 receptor. Inetetamab alone or together with tyrosine kinase inhibitors has antitumor activities .

HY-P1776

[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153)	Insulin Receptor	Metabolic Disease
[pTyr1146][pTyr1150][pTyr1151]Insulin Receptor (1142-1153) binds to insulin and can be used as insulin receptor tyrosine kinase substrates .

HY-101957

AG 1295 3 Publications Verification	PDGFR	Cardiovascular Disease
AG 1295 is a selective *platelet-derived growth factor receptor* (PDGFR)** tyrosine-kinase inhibitor. AG1295 abolishes autophosphorylation of the PDGFR whereas not affects the autophosphorylation of the EGF receptor .

HY-12806

AG1557	EGFR	Cancer
AG1557 is a specific and ATP competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, has a pIC₅₀ value of 8.194 .

HY-10501

SU14813 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

HY-10501A

SU14813 maleate 1 Publications Verification	PDGFR VEGFR c-Kit	Cancer
SU14813 maleate is a multi-targeted receptor tyrosine kinases inhibitor with IC₅₀s of 50, 2, 4, 15 nM for VEGFR2, VEGFR1, PDGFRβ and KIT.

HY-147316

TP-5801	Others	Cancer
TP-5801 is an orally active TNK1 (non-receptor **tyrosine kinase) inhibitor (IC₅₀**=1.40 nM), and shows anti-tumor activity .

HY-120857

BPIQ-II hydrochloride PD 158294	Others	Others
BPIQ-II is a linear imidazoloquinazoline that potently inhibits the tyrosine kinase activity of the epidermal growth factor receptor (EGFR; IC₅₀=8 pM). It is selective for EGFR over an assortment of other tyrosine and serine/threonine kinases. Cellular studies indicate that BPIQ-II can enter cells and very selectively shut down EGF-stimulated signal transmission by binding competitively at the ATP site of EGFR.

HY-118144

PD166326	BCRP Src	Cancer
PD166326 is a pyridopyrimidine-type inhibitor of **receptor tyrosine kinases, with IC₅₀s of 6 nM and 8 nM for Src and Abl**, respectively. PD166326 exhibits antileukemic activity .

HY-153012

Axl/Mer/CSF1R-IN-1	TAM Receptor c-Fms	Cancer
Axl/Mer-IN-1 (Compound 1) is an Axl/Mer receptor tyrosine kinase (Axl/Mer RTK) and CSF1R inhibitor with K_ds of <0.1 μM .

HY-147316A

TP-5801 TFA	Others	Cancer
TP-5801 TFA is an orally active TNK1 (non-receptor **tyrosine kinase) inhibitor (IC₅₀**=1.40 nM), and shows anti-tumor activity .

HY-15772S3

Asandeutertinib asandeutertinibum; Osimertinib-d₃; AZD-9291-d₃	EGFR	Cancer
Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with antineoplastic effect .

HY-144424

Trk-IN-11	Trk Receptor	Cancer
Trk-IN-11 (Compound 14h) is a potent inhibitor of TRK (IC₅₀ = 1.4, 1.8 nM, against TrkA, TrkA ^G595R, respectively). As a receptor tyrosine kinase (RTK), tropomyosin receptor kinase (Trk) is a key agent target in solid tumors. Trk-IN-11 has the potential for the research of cancer disease .

HY-112452

SU11652	VEGFR FGFR PDGFR c-Kit Apoptosis	Cancer
SU11652 is a potent receptor tyrosine kinase (RTK) inhibitor. SU11652 also inhibits several members of the split kinase family of RTKs, including VEGFR, FGFR, PDGFR, and Kit. SU11652 can be uesd for spontaneous cancers expressing Kit mutations research .

HY-13979

DDR1-IN-1 3 Publications Verification	Discoidin Domain Receptor	Cancer
DDR1-IN-1 is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC₅₀ of 105 nM; 4-fold less potent for DDR2 (IC₅₀ = 413 nM) .

HY-13979A

DDR1-IN-1 dihydrochloride	Discoidin Domain Receptor	Cancer
DDR1-IN-1 dihydrochloride is a potent and selective DDR1 receptor tyrosine kinase inhibitor with an IC₅₀ of 105 nM; 4-fold less potent for DDR2 (IC₅₀ = 413 nM) .

HY-111969

BT18 1 Publications Verification	GDNF Receptor	Neurological Disease
BT18 is a molecule mimic with function similar to glial cell line-derived neurotrophic factor (GDNF) . BT18 shows an effect on GDNF family receptor GFRα1 and RET receptor tyrosine kinase RetA function .

HY-128571

FLT3-IN-4	FLT3	Cancer
FLT3-IN-4 is a potent and orally effective Fms-like tyrosine receptor kinase 3 (FLT3; IC₅₀=7 nM) inhibitor for treating acute myelogenous leukemia .

HY-101959

Tyrphostin AG213 AG213	EGFR Topoisomerase	Cancer
Tyrphostin AG213 (AG213) is an inhibitor of epidermal growth factor receptor (EGFR) protein tyrosine kinase (IC₅₀=0.85 μM). Tyrphostin AG213 inhibits tyrosine kinase activity IC₅₀=2.4 μM) and topoisomerase II (IC₁₀₀=50 μM). Tyrphostin AG213 can induce nonapoptotic cell programmed death in tumor cells .

HY-13896

PD168393 2 Publications Verification	EGFR Autophagy Apoptosis	Cancer
PD168393?is a potent, selective and cell-permeable inhibitor of EGFR tyrosine kinase and ErbB2. PD168393 irreversiblely inactivates EGF receptor ( IC₅₀=0.7 nM) and is inactive against insulin receptor, PDGFR, FGFR and PKC .

HY-101837

CGP 53716	Others	Inflammation/Immunology
CGP 53716 is a potent protein tyrosine kinase inhibitor. CGP 53716 has selective activity of platelet-derived growth factor (PDGF) receptor. CGP 53716 can be used in the study of disease induced by abnormal cell proliferation induced by PDGF receptor activation .

HY-118203

SU4984	FGFR PDGFR Insulin Receptor	Cancer
SU4984 is a protein tyrosine kinase inhibitor, with an IC₅₀ of 10-20 μM for *fibroblast growth factor receptor* 1 (FGFR1)*. SU4984 is also inhibits platelet-derived growth factor receptor, and insulin receptor*. SU4984 can be used for the research of cancer .

HY-110367A

LCB 03-0110	Src	Others
LCB 03-0110, a thienopyridine derivative, is a potent pan-discoidin domain receptor/c-Src family tyrosine kinase inhibitor. LCB 03-0110 suppresses scar formation by inhibiting fibroblast and macrophage activation .

HY-156635

TIE-2/VEGFR-2 kinase-IN-3	Tie VEGFR	Cardiovascular Disease
TIE-2/VEGFR-2 kinase-IN-3, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC₅₀ values of 6.9 nM and 3.5 nM, respectively. TIE-2/VEGFR-2 kinase-IN-3 can be used for the research of angiogenesis .

HY-156637

TIE-2/VEGFR-2 kinase-IN-4	Tie VEGFR	Cardiovascular Disease
TIE-2/VEGFR-2 kinase-IN-4, benzimidazole, is a potent TIE-2 and VEGFR-2 tyrosine kinase receptors inhibitors with IC₅₀ values of 5.2 nM and 5.1 nM, respectively. TIE-2/VEGFR-2 kinase-IN-4 can be used for the research of angiogenesis .

Cat. No.	Product Name	Category	Target	Chemical Structure

HY-18963

Lavendustin A RG-14355	Structural Classification Microorganisms Classification of Application Fields Ketones, Aldehydes, Acids Source classification Phenols Polyphenols Disease Research Fields Cancer	EGFR
Lavendustin A (RG-14355) is a potent, selective and ATP-competitive inhibitor of epidermal growth factor receptor (EGFR) tyrosine kinase, with an IC₅₀ of 11 nM. Lavendustin A does not inhibit protein kinase A or C. Lavendustin A can suppress VEGF-induced angiogenesis .

HY-N0737A

Harmine 15+ Cited Publications Telepathine	Alkaloids Structural Classification Zygophyllaceae Peganum harmala Linn. Source classification Plants Indole Alkaloids	DYRK 5-HT Receptor
Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT_2A serotonin receptor, with an K_i of 397 nM .

HY-N6732

K-252a 10+ Cited Publications SF2370; Antibiotic K 252a; Antibiotic SF 2370	Alkaloids Structural Classification Microorganisms Classification of Application Fields Source classification Inflammation/Immunology Disease Research Fields Indole Alkaloids	PKC PKA CaMK Trk Receptor Autophagy Antibiotic
K-252a, a staurosporine analog, inhibits protein kinase, with IC₅₀ values of 470 nM, 140 nM, 270 nM, and 1.7 nM for PKC, PKA, Ca ²⁺/calmodulin-dependent kinase type II, and phosphorylase kinase, respectively . K-252a is a potent inhibitor (IC₅₀ of 3 nM) of the tyrosine protein kinase (TRK) activity of the NGF receptor gp140trk, the product of the trk protooncogene .

HY-N4201

β-Hydroxyisovalerylshikonin	Quinones Classification of Application Fields Source classification Phenols Polyphenols Plants Lithospermum erythrorhizon Sieb. et Zucc. Naphthalene Quinones Disease Research Fields Boraginaceae Cancer	EGFR Src
Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermum erythrorhizon, acts as a potent inhibitor of *protein tyrosine* kinases (PTK), with IC₅₀*s of 0.7μM and 1μM for EGFR and v-Src receptor*, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells .

HY-N11675

5-Hydroxy-TSU-68	Structural Classification Alkaloids Monophenols Pyrrole Alkaloids Source classification Phenols Endogenous metabolite	Endogenous Metabolite
5-Hydroxy-TSU-68 (compound M1) is the 5-hydroxylated indolinone derivative of TSU-68. TSU-68 is an anticancer agent that inhibits angiogenic receptor tyrosine kinases .

HY-N12041

Axl-IN-16	Structural Classification Natural Products Microorganisms Source classification	TAM Receptor HIF/HIF Prolyl-Hydroxylase
Axl-IN-16 is a dual inhibitor of Axl/HIF. Axl-IN-16 induces fruiting body formation of Flammulina velutipes. Axl-IN-16 inhibits hypoxia-inducible factor activity and receptor tyrosine kinase expression .

HY-N0737AR

Harmine (Standard)	Alkaloids Structural Classification Zygophyllaceae Peganum harmala Linn. Source classification Plants Indole Alkaloids	DYRK 5-HT Receptor
Harmine (Standard) is the analytical standard of Harmine. This product is intended for research and analytical applications. Harmine is a natural dual-specificity tyrosine phosphorylation-regulated kinase (DYRK) inhibitor with anticancer and anti-inflammatory activities. Harmine has a high affinity of 5-HT2A serotonin receptor, with an Ki of 397 nM .

Cat. No.	Product Name	Chemical Structure

HY-10331S

Regorafenib-d3
Regorafenib-d₃ is a deuterium labeled Regorafenib. Regorafenib is a multi-targeted receptor tyrosine kinase inhibitor[1].

HY-13016S

Cabozantinib-d6
Cabozantinib-d₆ is the deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively[1][2][3].

HY-10255AS

Sunitinib-d10
Sunitinib-d₁₀ is a deuterium labeled Sunitinib. Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

HY-15772S3

Asandeutertinib
Asandeutertinib (Osimertinib-d3; AZD-9291-d3) is a epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, with antineoplastic effect .

HY-112096S

eCF506-d5
eCF506-d₅ is deuterated labeled eCF506 (HY-112096). eCF506 is a highly potent and orally bioavailable inhibitor of the non-receptor tyrosine kinase Src with an IC₅₀ of less than 0.5 nM.

HY-13016S1

Cabozantinib-d4
Cabozantinib-d₄ is deuterium labeled Cabozantinib. Cabozantinib is a potent multiple receptor tyrosine kinases (RTKs) inhibitor that inhibits VEGFR2, c-Met, Kit, Axl and Flt3 with IC50s of 0.035, 1.3, 4.6, 7 and 11.3 nM, respectively.

HY-10255AS1

Sunitinib-d4
Sunitinib-d₄ is the deuterium labeled Sunitinib. Sunitinib (SU 11248) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 80 nM and 2 nM for VEGFR2 and PDGFRβ, respectively[1]. Sunitinib, an ATP-competitive inhibitor, effectively inhibits autophosphorylation of Ire1α by inhibiting autophosphorylation and consequent RNase activation[2].

HY-10330S

Toceranib-d8
Toceranib-d₈ is the deuterium labeled Toceranib. Toceranib (SU11654) is an orally active receptor tyrosine kinase (RTK) inhibitor, and it potently inhibits PDGFR, VEGFR, and Kit with Kis of 5 and 6 nM for PDGFRβ and Flk-1/KDR, respectively. Toceranib (SU11654) has antitumor and antiangiogenic activity, and used in the treatment of canine mast cell tumors[1][2].

HY-10331S1

Regorafenib-13C,d3
Regorafenib- ¹³C,d₃ is the ¹³C- and deuterium labeled Regorafenib. Regorafenib (BAY 73-4506) is a multi-targeted receptor tyrosine kinase inhibitor with IC50s of 13/4.2/46, 22, 7, 1.5 and 2.5 nM for VEGFR1/2/3, PDGFRβ, Kit, RET and Raf-1, respectively.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Species:	Human (94) Rhesus Macaque (10) Mouse (28) Rat (14) Cynomolgus (5) Canine (2)
Tag:	His (90) SUMO (1) Tag Free (11) Avi (14) Myc (1) GST (13) Fc (42) Flag (7) B2M (1)
Source:	HEK293 (119) Sf9 insect cells (1) Sf9 insect cells (24) P. pastoris (2) E. coli (5)


Products	In-stock - + Add to Cart
Cat. No.
Species
Source
Tag
Accession
Gene ID
Molecular Weight
Purity
Endotoxin Level
Biological Activity
Appearance
Formulation
Storage & Stability
Shipping
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote


Products	In-stock - + Add to Cart
Cat. No.
Host
Reactivity
Application
Dilution Ratio
Molecular Weight
Conjugation
Clonality
Immunogen
Appearance
Isotype
Gene ID
SwissProt ID
Purity
Formulation
Free Sample	Yes No
Size	* This product has been "discontinued". Optimized version of product available: / In-stock - + Add to Cart Get quote

Receptor tyrosine kinase

Inhibitors & Agonists

Screening Libraries

Fluorescent Dye

Biochemical Assay Reagents

Peptides

Inhibitory Antibodies

NaturalProducts

Recombinant Proteins

Isotope-Labeled Compounds

Antibodies

Click Chemistry

Natural
Products